Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy

Abstract Background MEK inhibitors (MEKi) were shown to be clinically insufficiently effective in patients suffering from BRAF wild-type (BRAF WT) melanoma, even if the MAPK pathway was constitutively activated due to mutations in NRAS or NF-1. Thus, novel combinations are needed to increase the eff...

Descripció completa

Dades bibliogràfiques

Autors principals:	Francisco Meraz-Torres, Heike Niessner, Sarah Plöger, Simon Riel, Barbara Schörg, Nicolas Casadei, Manfred Kneilling, Martin Schaller, Lukas Flatz, Boris Macek, Thomas Eigentler, Olaf Rieß, Claus Garbe, Teresa Amaral, Tobias Sinnberg
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-01-01
Col·lecció:	Journal of Experimental & Clinical Cancer Research
Matèries:	Melanoma BRAF Disulfiram Trametinib MEK inhibitor ER stress
Accés en línia:	https://doi.org/10.1186/s13046-023-02941-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!